Afschin Gandjour
Professor of Health Management • Professor
Professor of Health Management
Dr. Afschin Gandjour is a physician-economist and professor of health management at the Frankfurt School of Finance & Management. With formal training in medicine (MD), health economics and management (MBA, PhD), and philosophy (MA), he combines interdisciplinary expertise in clinical medicine, economics, and ethics.
His research focuses on health economics, cost-effectiveness analysis, pharmaceutical pricing, and public health policy.
His research focuses on health economics, cost-effectiveness analysis, pharmaceutical pricing, and public health policy.
Selected Research Rankings
(ScholarGPS 2024 and Wirtschaftswoche 2024)
#1 German health economists (lifetime research performance)
#12 Health economists worldwide (research performance, past 5 years)
#12 German business administration scholars (lifetime research output)
- Economics & Law Department
- Professor
- Faculty
PUBLICATIONS
Gandjour, A., 2024. Comment on: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?", Applied Health Economics and Health Policy Vol. 22(1), pp. 125-126.
Gandjour, A., 2024. Negative Drug Pricing in the Context of Cost-Effectiveness Analysis: a Consistency Examination, Value in Health Vol. 27(1), p. 131.
Gandjour, A., 2024. Perspectives on interpersonal utility comparisons: an analysis of selected models, The Journal of Philosophical Economics Vol. 17.
Gandjour, A., 2024. The impact of health expenditures on mortality in England: Assessing plausibility, Health Policy Vol. 143(105038).
Gandjour, A., 2024. Value-based pricing of cognitive behavioral therapy for depression in primary care: an economic evaluation, BMC Health Services Research Vol. 24(317).
Gandjour, A., 2023. A Bayesian citation indicator of individual scientific performance combining impact factor and citation rate, International Public Management Review Vol. 23(1), pp. 19-27.
Gandjour, A., 2023. A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany, Applied Health Economics and Health Policy Vol. 21(4), pp. 627-635.
Gandjour, A., 2023. Cost-effectiveness of future lockdown policies against the COVID-19 pandemic, Health Services Management Research Vol. 36(1), pp. 51-62.
Gandjour, A., 2023. Funding criteria for health services research in Germany: an economic perspective, International Public Management Review Vol. 23(1), pp. 49-58.
Gandjour, A., 2023. Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment, The European Journal of Health Economics Vol. 24(7), pp. 1243-1244.
Gandjour, A., 2023. Long COVID: Costs for the German economy and health care and pension system, BMC Health Services Research Vol. 23(641).
Gandjour, A., 2023. Long COVID: costs for the German economy and health care and pension system., BMC Health Services Research p. 641.
Gandjour, A., 2023. New Development: Increasing vaccination uptake in repeated COVID-19 vaccination mandates, Public Money and Management (2) pp. 191-193.
Gandjour, A., 2023. New development: Increasing vaccination uptake in repeated Covid 19 vaccination mandates, Public Money and Management Vol. 43(2), pp. 191-193.
Gandjour, A., 2023. Optimal allocation of scarce PCR tests during the COVID-19 pandemic, PLOS ONE Vol. 18(6).
Gandjour, A., 2023. Optimal allocation of scarce PCR tests during the COVID-19 pandemic, PLOS ONE.
Gandjour, A., 2023. Value-based pricing of add-on life-extending medicines based on economic evaluation, British Journal of Healthcare Management Vol. 29(8).
Gandjour, A., 2022. Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer's perspective, BMC Health Services Research Vol. 22(47).
Gandjour, A., 2022. COVID-19 and the forgone health benefits of elective operations, BMC Health Services Research Vol. 22(1545).
Gandjour, A., 2022. Comment on "Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective": Letter to the Editor, PharmacoEconomics Vol. 40, pp. 929-930.
Gandjour, A., 2022. Cost-effectiveness of future lockdown policies against the COVID-19 pandemic., Health Services Management Research (1) pp. 51-62.
Gandjour, A., 2022. Demonstrating the value of cancer biomarkers at the population level, The European Journal of Health Economics Vol. 23, pp. 755-756.
Gandjour, A., 2022. Demonstrating the value of cancer biomarkers at the population level, The European Journal of Health Economics (4) pp. 755-756.
Gandjour, A., 2022. Financial Incentives in the Path to Recovery from the COVID-19 Pandemic, Applied Health Economics and Health Policy Vol. 20(1), pp. 5-8.
Gandjour, A., 2022. Financial incentives in the path to recovery from the COVID-19 pandemic [editorial], Applied Health Economics and Health Policy Vol. 20(1), pp. 5-8.
Luyckx, V., Rule, A., Tuttle, K., Delanaye, P., Liapis, H., Gandjour, A., Romagnani, P., Anders, H., 2022. Nephron overload as a therapeutic target to maximize kidney lifespan, Nature Reviews Nephrology Vol. 18(3), pp. 171-183.
Gandjour, A., 2022. Nutzen und Risiken von Corona-Selbsttests aus Verbrauchersicht, Das Gesundheitswesen Vol. 84(2), pp. 91-92.
Gandjour, A., 2022. Optimal Sample Size Calculation for Clinical Research under a Budget Constraint: Letter, Medical Decision Making Vol. 42(4), pp. 417-418.
Gandjour, A., 2022. Optimal sample size calculation for clinical research under a budget constraint, Medical Decision Making Vol. 42(4), pp. 417-418.
Kourouklis, D., Gandjour, A., 2022. Pharmaceutical Spending and Early-Stage Innovation in EU Countries, Industry and Innovation Vol. 29(10), pp. 1141-1170.
Gandjour, A., 2022. The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany, The Quarterly Review of Economics and Finance Vol. 84, pp. 502-509.
Gandjour, A., 2022. Vaccination Mandates, Physically Forced Vaccination, and Rationing in the Intensive Care Unit: Searching for Ethical Coherence in the COVID-19 Pandemic, The American Journal of Bioethics Vol. 22(11), pp. 11-14.
Gandjour, A., 2022. Value-based pricing of a COVID-19 vaccine, The Quarterly Review of Economics and Finance Vol. 84(May), pp. 1-8.
Gandjour, A., 2021. A parsimonious model to validate cost-effectiveness analyses on preventive health care, BMC Health Services Research Vol. 21(Article-No. 1213).
Gandjour, A., 2021. Deterministic Sensitivity Analysis Under Ignorance, PharmacoEconomics Vol. 39(10), pp. 1197-1198.
Gandjour, A., 2021. Deterministic sensitivity analysis under ignorance, PharmacoEconomics Vol. 39(10), pp. 1197-1198.
Gandjour, A., 2021. How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness?: A Cost-effectiveness Analysis for COVID-19 in Germany, Applied Health Economics and Health Policy Vol. 19(2), pp. 181-190.
Gandjour, A., 2021. Inadequate Explanation: Correspondence, Deutsches Ärzteblatt Vol. 118(27-28), pp. 488-489.
Gandjour, A., 2021. The price of curing cancer, BMC Health Services Research Vol. 21(Article-No. 1328).
Gandjour, A., 2020. A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency, BMC Health Services Research Vol. 20(Article-No. 240).
Gandjour, A., Kourouklis, D., 2020. A survey analyzing assumptions for rational decision making in health care, Economics Bulletin Vol. 40(1), pp. 828-836.
Gandjour, A., 2020. Autonomy, coercion, and public health care guarantees: the uptake of sofosbuvir in Germany, Cambridge Quarterly of Healthcare Ethics Vol. 30(1), pp. 90-102.
Gandjour, A., Ostwald, D., 2020. Cost-Effectiveness of Secukinumab Versus other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany, Applied Health Economics and Health Policy Vol. 18(1), pp. 109-125.
Gandjour, A., Armsen, W., Wehmeyer, W., Multmeier, J., Tschulena, U., 2020. Costs of patients with chronic kidney disease in Germany, PLOS ONE Vol. 15(4)(Art.-No. e0231375).
Gandjour, A., 2020. Defining comparators according to IQWiG's efficiency-frontier method [letter], Value in Health Vol. 23(5), pp. 674-675.
Gandjour, A., 2020. Die Rolle der Zahl verfügbarer Intensivbetten bei der Bewältigung der ersten COVID-19-Welle: Leserbrief, Das Gesundheitswesen Jg. 82(12), pp. 938-939.
Gandjour, A., Schüßler, S., Hammerschmidt, T., Dintsios, C., 2020. Predictors of negotiated prices for new drugs in Germany, The European Journal of Health Economics Vol. 21(8), pp. 1049-1057.
Gandjour, A., 2020. Trends in rates of orthopedic surgery in Germany: the good, the bad, and the ugly, The European Journal of Health Economics Vol. 21(4), pp. 663-664.
Gandjour, A., 2020. Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWIG, BMC Health Services Research Vol. 20(Article-No. 343).
Shaikh, M., Gandjour, A., 2019. Pharmaceutical expenditure and gross domestic product: evidence of simultaneous effects from a two-step instrumental variables strategy, Health Economics Vol. 28(1), pp. 102-122.
Mensch, A., Beck, T., Civello, D., Kunigkeit, C., Lachmann, N., Stock, S., Gandjour, A., Müller, D., 2018. Applying GRADE criteria to cost-effectiveness modeling studies, PharmacoEconomics Vol. 36(8), pp. 987-994.
Schlander, M., Dintsios, C., Gandjour, A., 2018. Budgetary impact and cost drivers of drugs for rare and ultra-rare diseases, Value in Health Vol. 21(5), pp. 525-531.
Gandjour, A., 2018. Comment on "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany", European Journal of Health Economics Vol. 18(3), pp. 273-292.
Gandjour, A., 2018. Patient preferences: a Trojan horse for evidence-based medicine?, European Journal of Health Economics Vol. 19(1), pp. 167-172.
Gandjour, A., 2018. Rewards for social health insurance enrollees: a conceptual framework and ethical analysis, Das Gesundheitswesen Jg. 80(12), pp. 1104-1106.
Gandjour, A., Ostwald, D., 2018. Sacubitril/valsartan (LCZ696) - a novel treatment for heart failure and its estimated cost-effectiveness, budget impact, and disease burden reduction in Germany, PharmacoEconomics Vol. 36(10), pp. 1285-1296.
Gandjour, A., 2018. Underuse of innovative medicines in Germany: a justification for government intervention?, Health Policy Vol. 122(12), pp. 1283-1286.
Gandjour, A., 2017. Comment on: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation", PharmacoEconomics Vol. 35(5), pp. 603-604.
Gandjour, A., 2016. Comment on "The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011", Applied Health Economics and Health Policy Vol. 14(2), p. 241.
Gandjour, A., 2016. Comment on: "The cost effectiveness of high-dose versus conventional haemodialysis: a systematic review", Applied Health Economics and Health Policy Vol. 14(2), pp. 185-193.
Gandjour, A., 2016. Limiting free pricing of new innovative drugs after launch: a necessity for payers?, Applied Health Economics and Health Policy Vol. 14(5), pp. 507-509.
Gandjour, A., 2016. Prioritizing health services research: an economic perspective, European Journal of Health Economics Vol. 17(4), pp. 375-377.
Adarkwah, C., Sadoghi, A., Gandjour, A., 2016. Should Cost-Effectiveness Analysis Include the Cost of Consumption Activities?: An Empirical Investigation, Health Economics Vol. 25(2), pp. 249-256.
Gandjour, A., 2015. A model to optimize investments in health technologies, quality of care and research, Applied Economics Vol. 47(20), pp. 2031-2039.
Gandjour, A., Tschulena, U., Steppan, S., Gatti, E., 2015. A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 15(2), pp. 341-347.
Gandjour, A., 2015. Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 15(1), pp. 43-46.
Schlander, M., Adarkwah, C., Gandjour, A., 2015. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 15(1), pp. 171-179.
Gandjour, A., 2015. Comment on "Healthy decisions: towards uncertainty tolerance in healthcare policy", PharmacoEconomics Vol. 33(9), pp. 981-982.
Gandjour, A., 2015. Comment on "Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care", European Journal of Health Economics Vol. 16(4), pp. 451-452.
Gandjour, A., 2015. Commentary to: "Cost of poor adherence to anti-hypertensive therapy in five European countries", European Journal of Health Economics Vol. 16(8), p. 907.
Gandjour, A., 2015. Convergence of decision rules for value-based pricing of new innovative drugs, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 15(2), pp. 209-213.
Lévesque, R., Marcelli, D., Cardinal, H., Caron, M., Grooteman, M., Bots, M., Blankestijn, P., Nubé, M., Grassmann, A., Canaud, B., Gandjour, A., 2015. Cost-effectiveness analysis of high-efficiency hemodiafiltration vs. low-flux hemodialysis based on the Canadian arm of the CONTRAST study, Applied Health Economics and Health Policy Vol. 13(6), pp. 647-659.
Gandjour, A., 2015. Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule, International Journal of Health Planning and Management Vol. 30(4), pp. 395-402.
Müller, D., Pullenayegum, E., Gandjour, A., 2015. Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses, European Journal of Health Economics Vol. 16(2), pp. 219-223.
Berghaus, S., Müller, D., Gandjour, A., Civello, D., Stock, S., 2015. Osteoporosis in German men: a cost-of-illness study, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 15(3), pp. 531-537.
Gandjour, A., 2015. Ressourcenallokation im Gesundheitswesen und die Rolle individueller Autonomie, Das Gesundheitswesen Jg. 77(3), pp. 178-179.
Gandjour, A., 2014. Capturing disutility from waiting time, PharmacoEconomics Vol. 32(4), pp. 423-424.
Gandjour, A., 2014. Comment on "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines", PharmacoEconomics Vol. 32(12), pp. 1245-1246.
Gandjour, A., 2014. Considering productivity loss in cost-effectiveness analysis: a new approach, European Journal of Health Economics Vol. 15(8), pp. 787-790.
Gandjour, A., Gafni, A., Schlander, M., 2014. Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 14(1), pp. 123-129.
Gandjour, A., Müller, D., 2014. Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach, Applied Health Economics and Health Policy Vol. 12(5), pp. 471-476.
Gandjour, A., 2014. Health care expenditures from living longer: how much do they matter, International Journal of Health Planning and Management Vol. 29(1), pp. 43-51.
Gandjour, A., 2014. Kosten-Nutzen-Analyse im Gesundheitswesen basierend auf dem Capability Approach: Cost-effectiveness analysis in health care based on the capability approach, Das Gesundheitswesen Jg. 76(10), pp. 645-646.
Gandjour, A., Chernyak, N., Icks, A., Gafni, A., 2014. Public acceptance of different approaches to determine drug reimbursement prices and whether it is influenced by framing: an empirical evaluation in Germany, International Journal of Public Sector Management Vol. 27(6), pp. 501-511.
Gandjour, A., 2014. Welfare gains and losses caused by clinical practice guidelines, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 14(1), pp. 27-33.
Gandjour, A., 2013. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG), Health Services Management Research Vol. 26(4), pp. 103-109.
Stollenwerk, B., Gandjour, A., Lüngen, M., Siebert, U., 2013. Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation, European Journal of Health Economics Vol. 14(6), pp. 1035-1048.
Gandjour, A., Gafni, A., 2013. Internal validation of models with several interventions, European Journal of Health Economics Vol. 14(6), pp. 901-909.
Gandjour, A., 2013. Reference pricing and price negotiations for innovative new drugs: viable policies in the long term?, PharmacoEconomics Vol. 31(1), pp. 11-14.
Gandjour, A., 2013. Validation of models that estimate the cost-effectiveness of improving patient adherence, Value in Health Vol. 16(8), pp. 1170-1171.
Gandjour, A., 2012. Caregivers' quality of life and economic evaluations, PharmacoEconomics Vol. 30(9), pp. 857-858.
Gandjour, A., Ku-Goto, M., Ho, V., 2012. Comparing the validity of different measures of illness severity: a hospital-level analysis for acute myocardial infarction, Health Services Management Research Vol. 25(3), pp. 138-143.
Müller, D., Pulm, J., Gandjour, A., 2012. Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review, Value in Health Vol. 15(2), pp. 284-298.
Gandjour, A., 2012. Cost-effectiveness of preventing weight gain and obesity: what we know and what we need to know, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 12(3), pp. 297-305.
Gandjour, A., 2012. Presenting Germany's drug pricing rule as a cost-per-QALY rule, Health Care Management Science Vol. 15(2), pp. 103-107.
Gandjour, A., 2012. Simplifying rules for optimal allocation of preventive care resources, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 12(2), pp. 231-235.
Gandjour, A., 2011. A Model to Transfer Trial-Based Pharmacoeconomic Analyses to Clinical Practice, PharmacoEconomics Vol. 29(2), pp. 97-105.
Gandjour, A., Chernyak, N., 2011. A prize system for drug innovation, Health Policy Vol. 102(2/3), pp. 170-177.
Adarkwah, C., Gandjour, A., Akkerman, M., Evers, S., 2011. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin inhibitors for the prevention of diabetic nephropathy in the Netherlands: a Markov model, PLoS ONE Vol. 6(10).
Adarkwah, C., Gandjour, A., 2011. Cost-effectiveness of angiotensin-converting enzyme inhibitors in non-diabetic advanced renal disease, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 11(2), pp. 215-223.
Gandjour, A., Holler, A., Adarkwah, C., 2011. Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II), Value in Health Vol. 14(6), pp. 812-817.
Mueller, D., Gandjour, A., 2011. Cost-effectiveness of secondary versus tertiary prevention for postmenopausal osteoporosis, Applied Health Economics and Health Policy Vol. 9(4), pp. 259-273.
Weyler, E., Gandjour, A., 2011. Empirical validation of patient versus population preferences in calculating QALYs, Health Services Research Vol. 46(5), pp. 1562-1574.
Gandjour, A., 2011. Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules, Applied Health Economics and Health Policy Vol. 9(2), pp. 65-71.
Gandjour, A., 2011. Prioritizing Comparative Effectiveness Research: are Drug and Implementation Trials Equally Worth Funding?, PharmacoEconomics Vol. 29(7), pp. 555-561.
Gandjour, A., 2011. Protocol-driven costs in trial-based pharmacoeconomic analyses, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 11(6), pp. 673-675.
Gandjour, A., Gafni, A., 2011. The German method for setting ceiling prices for drugs: in some cases less data are required, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 11(4), pp. 403-409.
Gandjour, A., 2010. A model to predict the cost-effectiveness of disease-management programs, Health Economics Vol. 19(6), pp. 697-715.
Adarkwah, C., Gandjour, A., 2010. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany, International Journal of Technology Assessment in Health Care Vol. 26(1), pp. 62-70.
Icks, A., Haastert, B., Gandjour, A., Chernyak, N., Rathmann, W., Giani, G., Rump, L., Trapp, R., Koch, M., 2010. Costs of dialysis: a regional population-based analysis, Nephrology Dialysis Transplantation Vol. 25(5), pp. 1647-1652.
Gandjour, A., 2010. Interpersonal comparison of welfare in Harsanyi's veil-of-ignorance model, Ethics and Economics Vol. 7(2).
Gandjour, A., 2010. Investment in quality improvement: how to maximize the return, Health Economics Vol. 19(1), pp. 31-42.
Icks, A., Chernyak, N., Bestehorn, K., Brüggenjürgen, B., Bruns, J., Damm, O., Dintsios, C., Dreinhöfer, K., Gandjour, A., Gerber, A., Greiner, W., Hermanek, P., Hessel, F., Heymann, R., Huppertz, E., Jacke, C., Kächele, H., Kilian, R., Klingenberger, D., Kolominsky-Rabas, P., Krämer, H., Krauth, C., Lüngen, M., Neumann, T., Porzsolt, F., Prenzler, A., Pueschner, F., Riedel, R., Rüther, A., Salize, H., Scharnetzky, E., Schwerd, W., Selbmann, H., Siebert, H., Stengel, D., Stock, S., Völler, H., Wasem, J., Schrappe, M., 2010. Methoden der gesundheitsökonomischen Evaluation in der Versorgungsforschung: Methods of health economic evaluation for health services research, Das Gesundheitswesen Jg. 72(12), pp. 917-933.
Gandjour, A., Gafni, A., 2010. The additive utility assumption of the QALY model revisited, Journal of Health Economics Vol. 29(2), pp. 325-328.
Gandjour, A., 2010. Theoretical Foundation of Patient v. Population Preferences in Calculating QALYs, Medical Decision Making Vol. 30(4), pp. 57-63.
Gandjour, A., 2009. A payer's perspective on the cost effectiveness of gastric bypass surgery, American Journal of Managed Care Vol. 15(11), pp. 826-828.
Gandjour, A., 2009. Aging diseases: do they prevent preventive health care from saving costs?, Health Economics Vol. 18(3), pp. 355-362.
Gandjour, A., 2009. Cost-effectiveness of cardioverter-defibrillators in heart failure patients, Europace Vol. 11(12), p. 1721.
Mueller, D., Gandjour, A., 2009. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women, Value in Health Vol. 12(8), pp. 1106-1116.
Kneis, K., Gandjour, A., 2009. Economic Evaluation of Sinfrontal® in the treatment of acute maxillary sinusitis in adults, Applied Health Economics and Health Policy Vol. 7(3), pp. 181-191.
Gandjour, A., 2009. Pharmaceutical Risk-Sharing Agreements, PharmacoEconomics Vol. 27(5), pp. 431-432.
Gandjour, A., 2008. Assessing the value of a future study, PharmacoEconomics Vol. 26(10), pp. 891-892.
Mueller, D., Gandjour, A., 2008. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women, Applied Health Economics and Health Policy Vol. 6(2/3), pp. 113-135.
Mueller, D., Weyler, E., Gandjour, A., 2008. Cost-effectiveness of postmenopausal osteoporosis screening and treatment based on ten-year fracture risk, PharmacoEconomics Vol. 26(6), pp. 513-536.
Gandjour, A., Weyler, E., 2008. Cost-effectiveness of preventing hip fractures by hip protectors in elderly institutionalized residents in Germany, Value in Health Vol. 11(7), pp. 1088-1095.
Gandjour, A., Ihle, P., Schubert, I., 2008. Einfluss der demographischen Entwicklung auf Gesundheitsausgaben in Deutschland: eine Analyse unter Berücksichtigung der Ausgaben Versterbender, Das Gesundheitswesen Jg. 70(2), pp. 77-80.
Gandjour, A., 2008. Incorporating feelings related to the uncertainty about future health in utility measurement, Health Economics Vol. 17(10), pp. 1207-1213.
Gandjour, A., 2008. Loss Aversion and Cost Effectiveness of Healthcare Programs, PharmacoEconomics Vol. 26(11), pp. 895-898.
Gandjour, A., 2008. Mutual dependency between capabilities and functionings in Amartya Sen's capability approach, Social Choice and Welfare Vol. 31(2), pp. 345-350.
Gandjour, A., 2008. What drives US competitiveness in mathematics and science?, Educational Studies Vol. 34(4), pp. 269-270.
Gandjour, A., Stock, S., 2007. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness, Health Policy Vol. 83(2), pp. 257-267.
Icks, A., Rathmann, W., Haastert, B., Gandjour, A., Holle, R., John, J., Giani, G., 2007. Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000, Diabetic Medicine Vol. 24(5), pp. 473-480.
Gandjour, A., 2007. Is it rational to pursue utilitarianism?, Ethical Perspectives Vol. 14(2), pp. 139-158.
Weyler, E., Gandjour, A., 2007. Sozioökonomische Bedeutung von Hüftfrakturen in Deutschland, Das Gesundheitswesen Jg. 69(11), pp. 601-606.
Gandjour, A., 2006. Consumption costs and earnings during added years of life: a reply to Nyman, Health Economics Vol. 15(3), pp. 315-317.
Gandjour, A., Weyler, E., 2006. Cost-effectiveness of referrals to high-volume hospitals: an analysis based on a probabilistic Markov model for hip fracture surgeries, Health Care Management Science Vol. 9(4), pp. 359-369.
Gandjour, A., Lauterbach, K., 2005. Does prevention save costs?: Considering deferral of the expensive last year of life, Journal of Health Economics Vol. 24(4), pp. 715-724.
Gandjour, A., Telzerow, A., Lauterbach, K., 2005. European comparison of costs and quality in the treatment of acute back pain, Spine Vol. 30(8), pp. 969-975.
Gandjour, A., Lauterbach, K., 2005. How much does it cost to change the behavior of health professionals?: A mathematical model and an application to academic detailing, Medical Decision Making Vol. 25(3), pp. 341-347.
Gandjour, A., Greb, J., Bomsdorf, E., Lauterbach, K., 2005. Impact of Demographic Changes on Healthcare Expenditures and Funding in the EU, Applied Health Economics and Health Policy Vol. 4(1), pp. 1-4.
Gandjour, A., Kerschbaum, T., Reis, A., Lauterbach, K., 2005. Technology assessment in dentistry: a comparison of the longevity and cost-effectiveness of inlays, International Journal of Technology Assessment in Health Care Vol. 21(3), pp. 319-325.
Gandjour, A., Lauterbach, K., 2005. Wann lohnt es, eine medizinische Ãœberversorgung abzubauen?: Das Beispiel der Verschreibung teurer Antihypertonika, Medizinische Klinik Vol. 100(9), pp. 535-541.
Gandjour, A., Neumann, I., Lauterbach, K., 2004. Appropriateness of invasive cardiovascular interventions in German hospitals (2000-2001): an evaluation using the RAND appropriateness criteria, Thoracic and Cardiovascular Surgeon Vol. 52(6), pp. 365-371.
Icks, A., Haastert, B., Gandjour, A., John, J., Löwel, H., Holle, R., Giani, G., Rathmann, W., 2004. Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA survey 2000, Diabetes Care Vol. 27(9), pp. 2120-2128.
Gandjour, A., Telzerow, A., Lauterbach, K., 2004. Costs and quality in the treatment of acute depression in primary care: a comparison between England, Germany, and Switzerland, International Clinical Psychopharmacology Vol. 19(4), pp. 201-208.
Icks, A., Rosenbauer, J., Rathmann, W., Haastert, B., Gandjour, A., Giani, G., 2004. Direct costs of care in Germany for diabetic children and adolescents in the early course after onset, Journal of Pediatric Endocrinology and Metabolism Bd. 17(11), pp. 1551-1559.
Icks, A., Rosenbauer, J., Haastert, B., Rathmann, W., Grabert, M., Gandjour, A., Giani, G., Holl, R., 2004. Direct costs of pediatric diabetes care in Germany and their predictors, Experimental and Clinical Endocrinology and Diabetes Jg. 112(6), pp. 302-309.
Gandjour, A., Lauterbach, K., 2004. Wann lohnt sich der Abbau medizinischer Unter- und Überversorgung?: Das Beispiel der Behandlung akuter Depressionen, Psychiatrische Praxis Jg. 31(3), pp. 157-162.
Gandjour, A., Schlichtherle, S., Neugebauer, A., Rüssmann, W., Lauterbach, K., 2003. A Cost-Effectiveness Model of Screening Strategies for Amblyopia and Risk Factors and Its Apllication in a German Setting, Optometry and vision science Vol. 80(3), pp. 259-269.
Gandjour, A., Lauterbach, K., 2003. An evidence-based disease-management program for patients with diabetic nephropathy, Journal of Nephrology Vol. 16(4), pp. 500-510.
Gandjour, A., Neumann, I., Lauterbach, K., 2003. Appropriateness of invasive cardiovascular interventions in German hospitals (2000-2001): an evaluation using the RAND appropriateness criteria, European Journal of Cardio-thoracic Surgery Vol. 24(4), pp. 571-577.
Gandjour, A., Lauterbach, K., 2003. Inductive reasoning in medicine: lessons from Carl Gustav Hempel's 'inductive-statistical' model, Journal of Evaluation in Clinical Practice Vol. 9(2), pp. 161-169.
Gandjour, A., Lauterbach, K., 2003. Internationaler Vergleich von Forschungsoutput und -produktivität im Fach Gesundheitsökonomie, Informatik, Biometrie und Epidemiologie in Medizin und Biologie Jg. 34(2), pp. 88-95.
Gandjour, A., Günster, C., Klauber, J., Lauterbach, K., 2003. Leistungsmengen von Krankenhäusern: eine bundesweite Analyse ausgewählter Interventionen, Gesundheitsökonomie und Qualitätsmanagement Jg. 8(2), pp. 102-104.
Heindel, W., Datené, S., Lauterbach, K., Gandjour, A., 2003. Prospektive Observationsstudie zur Abdomen-Sonographie im radiologischen Bereitschaftsdienst einer Universitätsklinik: Ansätze zur Rationalisierung, Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren Jg. 175(9), pp. 1207-1213.
Gandjour, A., Lauterbach, K., 2003. The practice-makes-perfect hypothesis in the context of other production concepts in health care, American journal of medical quality Vol. 18(4), pp. 171-175.
Gandjour, A., Bannenberg, A., Lauterbach, K., 2003. Threshold Volumes Associated With Higher Survival in Health Care: a Systematic Review, Medical Care Vol. 41(10), pp. 1129-1141.
Gandjour, A., Lauterbach, K., 2003. Utilitarian Theories Reconsidered: Common Misconceptions, More Recent Developments, and Health Policy Implications, Health Care Analysis Vol. 11(3), pp. 229-244.
Gandjour, A., Lauterbach, K., 2003. When is it Worth Introducing a Quality Improvement Program?: A Mathematical Model, Medical Decision Making Vol. 23(6), pp. 518-525.
Gloeckner, J., Gandjour, A., Lauterbach, K., 2002. A 'centres of excellence' approach in health care: points for and against, Applied Health Economics and Health Policy Vol. 1(3), pp. 120-122.
Gandjour, A., Kleinschmit, F., Littmann, V., Lauterbach, K., 2002. An evidence-based evaluation of quality and efficiency indicators, Quality management in health care Vol. 10(4), pp. 41-52.
Gandjour, A., Kleinschmit, F., Lauterbach, K., 2002. European comparison of costs and quality in the prevention of secondary complications in type 2 diabetes mellitus, Diabetic Medicine Vol. 19(7), pp. 594-601.
Gandjour, A., Kleinschmit, F., Lauterbach, K., 2002. European comparison of costs and quality in the treatment of acute myocardial infarction (2000-2001), European Heart Journal Vol. 23(11), pp. 858-868.
Gandjour, A., Lauterbach, K., 2002. Preventive care and the prospect of cost savings, European Journal of Health Economics Vol. 3(1), pp. 1-2.
Gandjour, A., Lauterbach, K., 2001. A method for assessing the cost-effectiveness and the break-even point of clinical practice guidelines, International Journal of Technology Assessment in Health Care Vol. 17(4), pp. 503-516.
Gandjour, A., Westenhöfer, J., Wirth, A., Fuchs, C., Lauterbach, K., 2001. Development process of an evidence-based guideline for the treatment of obesity, International Journal for Quality in Health Care Vol. 13(4), pp. 325-332.
Gandjour, A., 2001. Is Subjective Well-being a Useful Parameter for Allocating Resources among Public Interventions?, Health Care Analysis Vol. 9(4), pp. 437-447.
Gandjour, A., Lauterbach, K., 2001. Zusammenhang zwischen Leistungsmenge und Letalitätsrate: Leistungszahlen deutscher "Centres of excellence", Zeitschrift für Kardiologie Vol. 90(9), pp. 613-620.
Gandjour, A., Lauterbach, K., 2000. Allocating resources in health care: a comparison of cost-effectiveness analyses and evidence-based medicine, European Journal of Health Economics Vol. 1(2), pp. 116-121.
Dietlein, M., Weber, K., Gandjour, A., Thiessen, P., Lauterbach, K., Schicha, H., Moka, D., 2000. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results, European Journal of Nuclear Medicine Vol. 27(11), pp. 1598-1609.
Dietlein, M., Weber, K., Gandjour, A., Moka, D., Thiessen, P., Lauterbach, K., Schicha, H., 2000. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: decision analysis based on cost reimbursement in Germany, European Journal of Nuclear Medicine Jg. 27(10), pp. 1441-1456.
Krug, B., Lauterbach, K., Lackner, K., Boettge, M., Kessler, M., Gandjour, A., Lüngen, M., 2000. Qualitätskontrolle der ambulanten bildgebenden Diagnostik in Nordrhein-Westfalen: Darstellung und Diskussion des Studienkonzepts, Gesundheitsökonomie und Qualitätsmanagement (5) pp. 154-156.
Gandjour, A., 2000. The effect of managed care penetration on hospital staffing in Tennessee: 1991-1995, Managed Care Interface Vol. 13(9), pp. 62-66.
Gandjour, A., Lauterbach, K., 1999. Review of Quality-of-Life Evaluations in Patients with Angina Pectoris, PharmacoEconomics Vol. 16(2), pp. 141-152.
Gandjour, A., 2024. Negative Drug Pricing in the Context of Cost-Effectiveness Analysis: a Consistency Examination, Value in Health Vol. 27(1), p. 131.
Gandjour, A., 2024. Perspectives on interpersonal utility comparisons: an analysis of selected models, The Journal of Philosophical Economics Vol. 17.
Gandjour, A., 2024. The impact of health expenditures on mortality in England: Assessing plausibility, Health Policy Vol. 143(105038).
Gandjour, A., 2024. Value-based pricing of cognitive behavioral therapy for depression in primary care: an economic evaluation, BMC Health Services Research Vol. 24(317).
Gandjour, A., 2023. A Bayesian citation indicator of individual scientific performance combining impact factor and citation rate, International Public Management Review Vol. 23(1), pp. 19-27.
Gandjour, A., 2023. A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany, Applied Health Economics and Health Policy Vol. 21(4), pp. 627-635.
Gandjour, A., 2023. Cost-effectiveness of future lockdown policies against the COVID-19 pandemic, Health Services Management Research Vol. 36(1), pp. 51-62.
Gandjour, A., 2023. Funding criteria for health services research in Germany: an economic perspective, International Public Management Review Vol. 23(1), pp. 49-58.
Gandjour, A., 2023. Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment, The European Journal of Health Economics Vol. 24(7), pp. 1243-1244.
Gandjour, A., 2023. Long COVID: Costs for the German economy and health care and pension system, BMC Health Services Research Vol. 23(641).
Gandjour, A., 2023. Long COVID: costs for the German economy and health care and pension system., BMC Health Services Research p. 641.
Gandjour, A., 2023. New Development: Increasing vaccination uptake in repeated COVID-19 vaccination mandates, Public Money and Management (2) pp. 191-193.
Gandjour, A., 2023. New development: Increasing vaccination uptake in repeated Covid 19 vaccination mandates, Public Money and Management Vol. 43(2), pp. 191-193.
Gandjour, A., 2023. Optimal allocation of scarce PCR tests during the COVID-19 pandemic, PLOS ONE Vol. 18(6).
Gandjour, A., 2023. Optimal allocation of scarce PCR tests during the COVID-19 pandemic, PLOS ONE.
Gandjour, A., 2023. Value-based pricing of add-on life-extending medicines based on economic evaluation, British Journal of Healthcare Management Vol. 29(8).
Gandjour, A., 2022. Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer's perspective, BMC Health Services Research Vol. 22(47).
Gandjour, A., 2022. COVID-19 and the forgone health benefits of elective operations, BMC Health Services Research Vol. 22(1545).
Gandjour, A., 2022. Comment on "Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective": Letter to the Editor, PharmacoEconomics Vol. 40, pp. 929-930.
Gandjour, A., 2022. Cost-effectiveness of future lockdown policies against the COVID-19 pandemic., Health Services Management Research (1) pp. 51-62.
Gandjour, A., 2022. Demonstrating the value of cancer biomarkers at the population level, The European Journal of Health Economics Vol. 23, pp. 755-756.
Gandjour, A., 2022. Demonstrating the value of cancer biomarkers at the population level, The European Journal of Health Economics (4) pp. 755-756.
Gandjour, A., 2022. Financial Incentives in the Path to Recovery from the COVID-19 Pandemic, Applied Health Economics and Health Policy Vol. 20(1), pp. 5-8.
Gandjour, A., 2022. Financial incentives in the path to recovery from the COVID-19 pandemic [editorial], Applied Health Economics and Health Policy Vol. 20(1), pp. 5-8.
Luyckx, V., Rule, A., Tuttle, K., Delanaye, P., Liapis, H., Gandjour, A., Romagnani, P., Anders, H., 2022. Nephron overload as a therapeutic target to maximize kidney lifespan, Nature Reviews Nephrology Vol. 18(3), pp. 171-183.
Gandjour, A., 2022. Nutzen und Risiken von Corona-Selbsttests aus Verbrauchersicht, Das Gesundheitswesen Vol. 84(2), pp. 91-92.
Gandjour, A., 2022. Optimal Sample Size Calculation for Clinical Research under a Budget Constraint: Letter, Medical Decision Making Vol. 42(4), pp. 417-418.
Gandjour, A., 2022. Optimal sample size calculation for clinical research under a budget constraint, Medical Decision Making Vol. 42(4), pp. 417-418.
Kourouklis, D., Gandjour, A., 2022. Pharmaceutical Spending and Early-Stage Innovation in EU Countries, Industry and Innovation Vol. 29(10), pp. 1141-1170.
Gandjour, A., 2022. The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany, The Quarterly Review of Economics and Finance Vol. 84, pp. 502-509.
Gandjour, A., 2022. Vaccination Mandates, Physically Forced Vaccination, and Rationing in the Intensive Care Unit: Searching for Ethical Coherence in the COVID-19 Pandemic, The American Journal of Bioethics Vol. 22(11), pp. 11-14.
Gandjour, A., 2022. Value-based pricing of a COVID-19 vaccine, The Quarterly Review of Economics and Finance Vol. 84(May), pp. 1-8.
Gandjour, A., 2021. A parsimonious model to validate cost-effectiveness analyses on preventive health care, BMC Health Services Research Vol. 21(Article-No. 1213).
Gandjour, A., 2021. Deterministic Sensitivity Analysis Under Ignorance, PharmacoEconomics Vol. 39(10), pp. 1197-1198.
Gandjour, A., 2021. Deterministic sensitivity analysis under ignorance, PharmacoEconomics Vol. 39(10), pp. 1197-1198.
Gandjour, A., 2021. How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness?: A Cost-effectiveness Analysis for COVID-19 in Germany, Applied Health Economics and Health Policy Vol. 19(2), pp. 181-190.
Gandjour, A., 2021. Inadequate Explanation: Correspondence, Deutsches Ärzteblatt Vol. 118(27-28), pp. 488-489.
Gandjour, A., 2021. The price of curing cancer, BMC Health Services Research Vol. 21(Article-No. 1328).
Gandjour, A., 2020. A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency, BMC Health Services Research Vol. 20(Article-No. 240).
Gandjour, A., Kourouklis, D., 2020. A survey analyzing assumptions for rational decision making in health care, Economics Bulletin Vol. 40(1), pp. 828-836.
Gandjour, A., 2020. Autonomy, coercion, and public health care guarantees: the uptake of sofosbuvir in Germany, Cambridge Quarterly of Healthcare Ethics Vol. 30(1), pp. 90-102.
Gandjour, A., Ostwald, D., 2020. Cost-Effectiveness of Secukinumab Versus other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany, Applied Health Economics and Health Policy Vol. 18(1), pp. 109-125.
Gandjour, A., Armsen, W., Wehmeyer, W., Multmeier, J., Tschulena, U., 2020. Costs of patients with chronic kidney disease in Germany, PLOS ONE Vol. 15(4)(Art.-No. e0231375).
Gandjour, A., 2020. Defining comparators according to IQWiG's efficiency-frontier method [letter], Value in Health Vol. 23(5), pp. 674-675.
Gandjour, A., 2020. Die Rolle der Zahl verfügbarer Intensivbetten bei der Bewältigung der ersten COVID-19-Welle: Leserbrief, Das Gesundheitswesen Jg. 82(12), pp. 938-939.
Gandjour, A., Schüßler, S., Hammerschmidt, T., Dintsios, C., 2020. Predictors of negotiated prices for new drugs in Germany, The European Journal of Health Economics Vol. 21(8), pp. 1049-1057.
Gandjour, A., 2020. Trends in rates of orthopedic surgery in Germany: the good, the bad, and the ugly, The European Journal of Health Economics Vol. 21(4), pp. 663-664.
Gandjour, A., 2020. Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWIG, BMC Health Services Research Vol. 20(Article-No. 343).
Shaikh, M., Gandjour, A., 2019. Pharmaceutical expenditure and gross domestic product: evidence of simultaneous effects from a two-step instrumental variables strategy, Health Economics Vol. 28(1), pp. 102-122.
Mensch, A., Beck, T., Civello, D., Kunigkeit, C., Lachmann, N., Stock, S., Gandjour, A., Müller, D., 2018. Applying GRADE criteria to cost-effectiveness modeling studies, PharmacoEconomics Vol. 36(8), pp. 987-994.
Schlander, M., Dintsios, C., Gandjour, A., 2018. Budgetary impact and cost drivers of drugs for rare and ultra-rare diseases, Value in Health Vol. 21(5), pp. 525-531.
Gandjour, A., 2018. Comment on "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany", European Journal of Health Economics Vol. 18(3), pp. 273-292.
Gandjour, A., 2018. Patient preferences: a Trojan horse for evidence-based medicine?, European Journal of Health Economics Vol. 19(1), pp. 167-172.
Gandjour, A., 2018. Rewards for social health insurance enrollees: a conceptual framework and ethical analysis, Das Gesundheitswesen Jg. 80(12), pp. 1104-1106.
Gandjour, A., Ostwald, D., 2018. Sacubitril/valsartan (LCZ696) - a novel treatment for heart failure and its estimated cost-effectiveness, budget impact, and disease burden reduction in Germany, PharmacoEconomics Vol. 36(10), pp. 1285-1296.
Gandjour, A., 2018. Underuse of innovative medicines in Germany: a justification for government intervention?, Health Policy Vol. 122(12), pp. 1283-1286.
Gandjour, A., 2017. Comment on: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation", PharmacoEconomics Vol. 35(5), pp. 603-604.
Gandjour, A., 2016. Comment on "The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011", Applied Health Economics and Health Policy Vol. 14(2), p. 241.
Gandjour, A., 2016. Comment on: "The cost effectiveness of high-dose versus conventional haemodialysis: a systematic review", Applied Health Economics and Health Policy Vol. 14(2), pp. 185-193.
Gandjour, A., 2016. Limiting free pricing of new innovative drugs after launch: a necessity for payers?, Applied Health Economics and Health Policy Vol. 14(5), pp. 507-509.
Gandjour, A., 2016. Prioritizing health services research: an economic perspective, European Journal of Health Economics Vol. 17(4), pp. 375-377.
Adarkwah, C., Sadoghi, A., Gandjour, A., 2016. Should Cost-Effectiveness Analysis Include the Cost of Consumption Activities?: An Empirical Investigation, Health Economics Vol. 25(2), pp. 249-256.
Gandjour, A., 2015. A model to optimize investments in health technologies, quality of care and research, Applied Economics Vol. 47(20), pp. 2031-2039.
Gandjour, A., Tschulena, U., Steppan, S., Gatti, E., 2015. A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 15(2), pp. 341-347.
Gandjour, A., 2015. Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 15(1), pp. 43-46.
Schlander, M., Adarkwah, C., Gandjour, A., 2015. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 15(1), pp. 171-179.
Gandjour, A., 2015. Comment on "Healthy decisions: towards uncertainty tolerance in healthcare policy", PharmacoEconomics Vol. 33(9), pp. 981-982.
Gandjour, A., 2015. Comment on "Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care", European Journal of Health Economics Vol. 16(4), pp. 451-452.
Gandjour, A., 2015. Commentary to: "Cost of poor adherence to anti-hypertensive therapy in five European countries", European Journal of Health Economics Vol. 16(8), p. 907.
Gandjour, A., 2015. Convergence of decision rules for value-based pricing of new innovative drugs, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 15(2), pp. 209-213.
Lévesque, R., Marcelli, D., Cardinal, H., Caron, M., Grooteman, M., Bots, M., Blankestijn, P., Nubé, M., Grassmann, A., Canaud, B., Gandjour, A., 2015. Cost-effectiveness analysis of high-efficiency hemodiafiltration vs. low-flux hemodialysis based on the Canadian arm of the CONTRAST study, Applied Health Economics and Health Policy Vol. 13(6), pp. 647-659.
Gandjour, A., 2015. Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule, International Journal of Health Planning and Management Vol. 30(4), pp. 395-402.
Müller, D., Pullenayegum, E., Gandjour, A., 2015. Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses, European Journal of Health Economics Vol. 16(2), pp. 219-223.
Berghaus, S., Müller, D., Gandjour, A., Civello, D., Stock, S., 2015. Osteoporosis in German men: a cost-of-illness study, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 15(3), pp. 531-537.
Gandjour, A., 2015. Ressourcenallokation im Gesundheitswesen und die Rolle individueller Autonomie, Das Gesundheitswesen Jg. 77(3), pp. 178-179.
Gandjour, A., 2014. Capturing disutility from waiting time, PharmacoEconomics Vol. 32(4), pp. 423-424.
Gandjour, A., 2014. Comment on "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines", PharmacoEconomics Vol. 32(12), pp. 1245-1246.
Gandjour, A., 2014. Considering productivity loss in cost-effectiveness analysis: a new approach, European Journal of Health Economics Vol. 15(8), pp. 787-790.
Gandjour, A., Gafni, A., Schlander, M., 2014. Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 14(1), pp. 123-129.
Gandjour, A., Müller, D., 2014. Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach, Applied Health Economics and Health Policy Vol. 12(5), pp. 471-476.
Gandjour, A., 2014. Health care expenditures from living longer: how much do they matter, International Journal of Health Planning and Management Vol. 29(1), pp. 43-51.
Gandjour, A., 2014. Kosten-Nutzen-Analyse im Gesundheitswesen basierend auf dem Capability Approach: Cost-effectiveness analysis in health care based on the capability approach, Das Gesundheitswesen Jg. 76(10), pp. 645-646.
Gandjour, A., Chernyak, N., Icks, A., Gafni, A., 2014. Public acceptance of different approaches to determine drug reimbursement prices and whether it is influenced by framing: an empirical evaluation in Germany, International Journal of Public Sector Management Vol. 27(6), pp. 501-511.
Gandjour, A., 2014. Welfare gains and losses caused by clinical practice guidelines, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 14(1), pp. 27-33.
Gandjour, A., 2013. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG), Health Services Management Research Vol. 26(4), pp. 103-109.
Stollenwerk, B., Gandjour, A., Lüngen, M., Siebert, U., 2013. Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation, European Journal of Health Economics Vol. 14(6), pp. 1035-1048.
Gandjour, A., Gafni, A., 2013. Internal validation of models with several interventions, European Journal of Health Economics Vol. 14(6), pp. 901-909.
Gandjour, A., 2013. Reference pricing and price negotiations for innovative new drugs: viable policies in the long term?, PharmacoEconomics Vol. 31(1), pp. 11-14.
Gandjour, A., 2013. Validation of models that estimate the cost-effectiveness of improving patient adherence, Value in Health Vol. 16(8), pp. 1170-1171.
Gandjour, A., 2012. Caregivers' quality of life and economic evaluations, PharmacoEconomics Vol. 30(9), pp. 857-858.
Gandjour, A., Ku-Goto, M., Ho, V., 2012. Comparing the validity of different measures of illness severity: a hospital-level analysis for acute myocardial infarction, Health Services Management Research Vol. 25(3), pp. 138-143.
Müller, D., Pulm, J., Gandjour, A., 2012. Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review, Value in Health Vol. 15(2), pp. 284-298.
Gandjour, A., 2012. Cost-effectiveness of preventing weight gain and obesity: what we know and what we need to know, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 12(3), pp. 297-305.
Gandjour, A., 2012. Presenting Germany's drug pricing rule as a cost-per-QALY rule, Health Care Management Science Vol. 15(2), pp. 103-107.
Gandjour, A., 2012. Simplifying rules for optimal allocation of preventive care resources, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 12(2), pp. 231-235.
Gandjour, A., 2011. A Model to Transfer Trial-Based Pharmacoeconomic Analyses to Clinical Practice, PharmacoEconomics Vol. 29(2), pp. 97-105.
Gandjour, A., Chernyak, N., 2011. A prize system for drug innovation, Health Policy Vol. 102(2/3), pp. 170-177.
Adarkwah, C., Gandjour, A., Akkerman, M., Evers, S., 2011. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin inhibitors for the prevention of diabetic nephropathy in the Netherlands: a Markov model, PLoS ONE Vol. 6(10).
Adarkwah, C., Gandjour, A., 2011. Cost-effectiveness of angiotensin-converting enzyme inhibitors in non-diabetic advanced renal disease, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 11(2), pp. 215-223.
Gandjour, A., Holler, A., Adarkwah, C., 2011. Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II), Value in Health Vol. 14(6), pp. 812-817.
Mueller, D., Gandjour, A., 2011. Cost-effectiveness of secondary versus tertiary prevention for postmenopausal osteoporosis, Applied Health Economics and Health Policy Vol. 9(4), pp. 259-273.
Weyler, E., Gandjour, A., 2011. Empirical validation of patient versus population preferences in calculating QALYs, Health Services Research Vol. 46(5), pp. 1562-1574.
Gandjour, A., 2011. Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules, Applied Health Economics and Health Policy Vol. 9(2), pp. 65-71.
Gandjour, A., 2011. Prioritizing Comparative Effectiveness Research: are Drug and Implementation Trials Equally Worth Funding?, PharmacoEconomics Vol. 29(7), pp. 555-561.
Gandjour, A., 2011. Protocol-driven costs in trial-based pharmacoeconomic analyses, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 11(6), pp. 673-675.
Gandjour, A., Gafni, A., 2011. The German method for setting ceiling prices for drugs: in some cases less data are required, Expert Review of Pharmacoeconomics and Outcomes Research Vol. 11(4), pp. 403-409.
Gandjour, A., 2010. A model to predict the cost-effectiveness of disease-management programs, Health Economics Vol. 19(6), pp. 697-715.
Adarkwah, C., Gandjour, A., 2010. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany, International Journal of Technology Assessment in Health Care Vol. 26(1), pp. 62-70.
Icks, A., Haastert, B., Gandjour, A., Chernyak, N., Rathmann, W., Giani, G., Rump, L., Trapp, R., Koch, M., 2010. Costs of dialysis: a regional population-based analysis, Nephrology Dialysis Transplantation Vol. 25(5), pp. 1647-1652.
Gandjour, A., 2010. Interpersonal comparison of welfare in Harsanyi's veil-of-ignorance model, Ethics and Economics Vol. 7(2).
Gandjour, A., 2010. Investment in quality improvement: how to maximize the return, Health Economics Vol. 19(1), pp. 31-42.
Icks, A., Chernyak, N., Bestehorn, K., Brüggenjürgen, B., Bruns, J., Damm, O., Dintsios, C., Dreinhöfer, K., Gandjour, A., Gerber, A., Greiner, W., Hermanek, P., Hessel, F., Heymann, R., Huppertz, E., Jacke, C., Kächele, H., Kilian, R., Klingenberger, D., Kolominsky-Rabas, P., Krämer, H., Krauth, C., Lüngen, M., Neumann, T., Porzsolt, F., Prenzler, A., Pueschner, F., Riedel, R., Rüther, A., Salize, H., Scharnetzky, E., Schwerd, W., Selbmann, H., Siebert, H., Stengel, D., Stock, S., Völler, H., Wasem, J., Schrappe, M., 2010. Methoden der gesundheitsökonomischen Evaluation in der Versorgungsforschung: Methods of health economic evaluation for health services research, Das Gesundheitswesen Jg. 72(12), pp. 917-933.
Gandjour, A., Gafni, A., 2010. The additive utility assumption of the QALY model revisited, Journal of Health Economics Vol. 29(2), pp. 325-328.
Gandjour, A., 2010. Theoretical Foundation of Patient v. Population Preferences in Calculating QALYs, Medical Decision Making Vol. 30(4), pp. 57-63.
Gandjour, A., 2009. A payer's perspective on the cost effectiveness of gastric bypass surgery, American Journal of Managed Care Vol. 15(11), pp. 826-828.
Gandjour, A., 2009. Aging diseases: do they prevent preventive health care from saving costs?, Health Economics Vol. 18(3), pp. 355-362.
Gandjour, A., 2009. Cost-effectiveness of cardioverter-defibrillators in heart failure patients, Europace Vol. 11(12), p. 1721.
Mueller, D., Gandjour, A., 2009. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women, Value in Health Vol. 12(8), pp. 1106-1116.
Kneis, K., Gandjour, A., 2009. Economic Evaluation of Sinfrontal® in the treatment of acute maxillary sinusitis in adults, Applied Health Economics and Health Policy Vol. 7(3), pp. 181-191.
Gandjour, A., 2009. Pharmaceutical Risk-Sharing Agreements, PharmacoEconomics Vol. 27(5), pp. 431-432.
Gandjour, A., 2008. Assessing the value of a future study, PharmacoEconomics Vol. 26(10), pp. 891-892.
Mueller, D., Gandjour, A., 2008. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women, Applied Health Economics and Health Policy Vol. 6(2/3), pp. 113-135.
Mueller, D., Weyler, E., Gandjour, A., 2008. Cost-effectiveness of postmenopausal osteoporosis screening and treatment based on ten-year fracture risk, PharmacoEconomics Vol. 26(6), pp. 513-536.
Gandjour, A., Weyler, E., 2008. Cost-effectiveness of preventing hip fractures by hip protectors in elderly institutionalized residents in Germany, Value in Health Vol. 11(7), pp. 1088-1095.
Gandjour, A., Ihle, P., Schubert, I., 2008. Einfluss der demographischen Entwicklung auf Gesundheitsausgaben in Deutschland: eine Analyse unter Berücksichtigung der Ausgaben Versterbender, Das Gesundheitswesen Jg. 70(2), pp. 77-80.
Gandjour, A., 2008. Incorporating feelings related to the uncertainty about future health in utility measurement, Health Economics Vol. 17(10), pp. 1207-1213.
Gandjour, A., 2008. Loss Aversion and Cost Effectiveness of Healthcare Programs, PharmacoEconomics Vol. 26(11), pp. 895-898.
Gandjour, A., 2008. Mutual dependency between capabilities and functionings in Amartya Sen's capability approach, Social Choice and Welfare Vol. 31(2), pp. 345-350.
Gandjour, A., 2008. What drives US competitiveness in mathematics and science?, Educational Studies Vol. 34(4), pp. 269-270.
Gandjour, A., Stock, S., 2007. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness, Health Policy Vol. 83(2), pp. 257-267.
Icks, A., Rathmann, W., Haastert, B., Gandjour, A., Holle, R., John, J., Giani, G., 2007. Clinical and cost-effectiveness of primary prevention of type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000, Diabetic Medicine Vol. 24(5), pp. 473-480.
Gandjour, A., 2007. Is it rational to pursue utilitarianism?, Ethical Perspectives Vol. 14(2), pp. 139-158.
Weyler, E., Gandjour, A., 2007. Sozioökonomische Bedeutung von Hüftfrakturen in Deutschland, Das Gesundheitswesen Jg. 69(11), pp. 601-606.
Gandjour, A., 2006. Consumption costs and earnings during added years of life: a reply to Nyman, Health Economics Vol. 15(3), pp. 315-317.
Gandjour, A., Weyler, E., 2006. Cost-effectiveness of referrals to high-volume hospitals: an analysis based on a probabilistic Markov model for hip fracture surgeries, Health Care Management Science Vol. 9(4), pp. 359-369.
Gandjour, A., Lauterbach, K., 2005. Does prevention save costs?: Considering deferral of the expensive last year of life, Journal of Health Economics Vol. 24(4), pp. 715-724.
Gandjour, A., Telzerow, A., Lauterbach, K., 2005. European comparison of costs and quality in the treatment of acute back pain, Spine Vol. 30(8), pp. 969-975.
Gandjour, A., Lauterbach, K., 2005. How much does it cost to change the behavior of health professionals?: A mathematical model and an application to academic detailing, Medical Decision Making Vol. 25(3), pp. 341-347.
Gandjour, A., Greb, J., Bomsdorf, E., Lauterbach, K., 2005. Impact of Demographic Changes on Healthcare Expenditures and Funding in the EU, Applied Health Economics and Health Policy Vol. 4(1), pp. 1-4.
Gandjour, A., Kerschbaum, T., Reis, A., Lauterbach, K., 2005. Technology assessment in dentistry: a comparison of the longevity and cost-effectiveness of inlays, International Journal of Technology Assessment in Health Care Vol. 21(3), pp. 319-325.
Gandjour, A., Lauterbach, K., 2005. Wann lohnt es, eine medizinische Ãœberversorgung abzubauen?: Das Beispiel der Verschreibung teurer Antihypertonika, Medizinische Klinik Vol. 100(9), pp. 535-541.
Gandjour, A., Neumann, I., Lauterbach, K., 2004. Appropriateness of invasive cardiovascular interventions in German hospitals (2000-2001): an evaluation using the RAND appropriateness criteria, Thoracic and Cardiovascular Surgeon Vol. 52(6), pp. 365-371.
Icks, A., Haastert, B., Gandjour, A., John, J., Löwel, H., Holle, R., Giani, G., Rathmann, W., 2004. Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA survey 2000, Diabetes Care Vol. 27(9), pp. 2120-2128.
Gandjour, A., Telzerow, A., Lauterbach, K., 2004. Costs and quality in the treatment of acute depression in primary care: a comparison between England, Germany, and Switzerland, International Clinical Psychopharmacology Vol. 19(4), pp. 201-208.
Icks, A., Rosenbauer, J., Rathmann, W., Haastert, B., Gandjour, A., Giani, G., 2004. Direct costs of care in Germany for diabetic children and adolescents in the early course after onset, Journal of Pediatric Endocrinology and Metabolism Bd. 17(11), pp. 1551-1559.
Icks, A., Rosenbauer, J., Haastert, B., Rathmann, W., Grabert, M., Gandjour, A., Giani, G., Holl, R., 2004. Direct costs of pediatric diabetes care in Germany and their predictors, Experimental and Clinical Endocrinology and Diabetes Jg. 112(6), pp. 302-309.
Gandjour, A., Lauterbach, K., 2004. Wann lohnt sich der Abbau medizinischer Unter- und Überversorgung?: Das Beispiel der Behandlung akuter Depressionen, Psychiatrische Praxis Jg. 31(3), pp. 157-162.
Gandjour, A., Schlichtherle, S., Neugebauer, A., Rüssmann, W., Lauterbach, K., 2003. A Cost-Effectiveness Model of Screening Strategies for Amblyopia and Risk Factors and Its Apllication in a German Setting, Optometry and vision science Vol. 80(3), pp. 259-269.
Gandjour, A., Lauterbach, K., 2003. An evidence-based disease-management program for patients with diabetic nephropathy, Journal of Nephrology Vol. 16(4), pp. 500-510.
Gandjour, A., Neumann, I., Lauterbach, K., 2003. Appropriateness of invasive cardiovascular interventions in German hospitals (2000-2001): an evaluation using the RAND appropriateness criteria, European Journal of Cardio-thoracic Surgery Vol. 24(4), pp. 571-577.
Gandjour, A., Lauterbach, K., 2003. Inductive reasoning in medicine: lessons from Carl Gustav Hempel's 'inductive-statistical' model, Journal of Evaluation in Clinical Practice Vol. 9(2), pp. 161-169.
Gandjour, A., Lauterbach, K., 2003. Internationaler Vergleich von Forschungsoutput und -produktivität im Fach Gesundheitsökonomie, Informatik, Biometrie und Epidemiologie in Medizin und Biologie Jg. 34(2), pp. 88-95.
Gandjour, A., Günster, C., Klauber, J., Lauterbach, K., 2003. Leistungsmengen von Krankenhäusern: eine bundesweite Analyse ausgewählter Interventionen, Gesundheitsökonomie und Qualitätsmanagement Jg. 8(2), pp. 102-104.
Heindel, W., Datené, S., Lauterbach, K., Gandjour, A., 2003. Prospektive Observationsstudie zur Abdomen-Sonographie im radiologischen Bereitschaftsdienst einer Universitätsklinik: Ansätze zur Rationalisierung, Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren Jg. 175(9), pp. 1207-1213.
Gandjour, A., Lauterbach, K., 2003. The practice-makes-perfect hypothesis in the context of other production concepts in health care, American journal of medical quality Vol. 18(4), pp. 171-175.
Gandjour, A., Bannenberg, A., Lauterbach, K., 2003. Threshold Volumes Associated With Higher Survival in Health Care: a Systematic Review, Medical Care Vol. 41(10), pp. 1129-1141.
Gandjour, A., Lauterbach, K., 2003. Utilitarian Theories Reconsidered: Common Misconceptions, More Recent Developments, and Health Policy Implications, Health Care Analysis Vol. 11(3), pp. 229-244.
Gandjour, A., Lauterbach, K., 2003. When is it Worth Introducing a Quality Improvement Program?: A Mathematical Model, Medical Decision Making Vol. 23(6), pp. 518-525.
Gloeckner, J., Gandjour, A., Lauterbach, K., 2002. A 'centres of excellence' approach in health care: points for and against, Applied Health Economics and Health Policy Vol. 1(3), pp. 120-122.
Gandjour, A., Kleinschmit, F., Littmann, V., Lauterbach, K., 2002. An evidence-based evaluation of quality and efficiency indicators, Quality management in health care Vol. 10(4), pp. 41-52.
Gandjour, A., Kleinschmit, F., Lauterbach, K., 2002. European comparison of costs and quality in the prevention of secondary complications in type 2 diabetes mellitus, Diabetic Medicine Vol. 19(7), pp. 594-601.
Gandjour, A., Kleinschmit, F., Lauterbach, K., 2002. European comparison of costs and quality in the treatment of acute myocardial infarction (2000-2001), European Heart Journal Vol. 23(11), pp. 858-868.
Gandjour, A., Lauterbach, K., 2002. Preventive care and the prospect of cost savings, European Journal of Health Economics Vol. 3(1), pp. 1-2.
Gandjour, A., Lauterbach, K., 2001. A method for assessing the cost-effectiveness and the break-even point of clinical practice guidelines, International Journal of Technology Assessment in Health Care Vol. 17(4), pp. 503-516.
Gandjour, A., Westenhöfer, J., Wirth, A., Fuchs, C., Lauterbach, K., 2001. Development process of an evidence-based guideline for the treatment of obesity, International Journal for Quality in Health Care Vol. 13(4), pp. 325-332.
Gandjour, A., 2001. Is Subjective Well-being a Useful Parameter for Allocating Resources among Public Interventions?, Health Care Analysis Vol. 9(4), pp. 437-447.
Gandjour, A., Lauterbach, K., 2001. Zusammenhang zwischen Leistungsmenge und Letalitätsrate: Leistungszahlen deutscher "Centres of excellence", Zeitschrift für Kardiologie Vol. 90(9), pp. 613-620.
Gandjour, A., Lauterbach, K., 2000. Allocating resources in health care: a comparison of cost-effectiveness analyses and evidence-based medicine, European Journal of Health Economics Vol. 1(2), pp. 116-121.
Dietlein, M., Weber, K., Gandjour, A., Thiessen, P., Lauterbach, K., Schicha, H., Moka, D., 2000. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results, European Journal of Nuclear Medicine Vol. 27(11), pp. 1598-1609.
Dietlein, M., Weber, K., Gandjour, A., Moka, D., Thiessen, P., Lauterbach, K., Schicha, H., 2000. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: decision analysis based on cost reimbursement in Germany, European Journal of Nuclear Medicine Jg. 27(10), pp. 1441-1456.
Krug, B., Lauterbach, K., Lackner, K., Boettge, M., Kessler, M., Gandjour, A., Lüngen, M., 2000. Qualitätskontrolle der ambulanten bildgebenden Diagnostik in Nordrhein-Westfalen: Darstellung und Diskussion des Studienkonzepts, Gesundheitsökonomie und Qualitätsmanagement (5) pp. 154-156.
Gandjour, A., 2000. The effect of managed care penetration on hospital staffing in Tennessee: 1991-1995, Managed Care Interface Vol. 13(9), pp. 62-66.
Gandjour, A., Lauterbach, K., 1999. Review of Quality-of-Life Evaluations in Patients with Angina Pectoris, PharmacoEconomics Vol. 16(2), pp. 141-152.
Gandjour, A., 2001, Angemessenheit in der Gesundheitsversorgung: Länderbericht Deutschland, in: Bundesministerium für Gesundheit (ed): Angemessenheit medizinischer Leistungen, Baden-Baden: Nomos, pp. 77-83.
Gandjour, A., 2002. Anwendung der betriebswirtschaftlichen Produktionstheorie im Krankenhaussektor, Weiden: eurotrans-Verl. (Köln, Univ., Diss., 2002.)
Gandjour, A., 2001. Wirtschaftlichkeitsanalysen im Gesundheitswesen: Entwicklung mathematischer Schwellenwertmodelle, Habil., Köln, Univ.
Gandjour, A., 1994. Pharmakologische Charakterisierung von Prostanoid-Rezeptoren an isolierten Magenschleimzellen des Schweines, Diss., Hannover, Medizinische Hochschule.
Gandjour, A., 2001. Wirtschaftlichkeitsanalysen im Gesundheitswesen: Entwicklung mathematischer Schwellenwertmodelle, Habil., Köln, Univ.
Gandjour, A., 1994. Pharmakologische Charakterisierung von Prostanoid-Rezeptoren an isolierten Magenschleimzellen des Schweines, Diss., Hannover, Medizinische Hochschule.
Gandjour, A., 2003, Wirtschaftliche Effekte ärztlicher Behandlungsleitlinien, in: Frank Dietrich, Michael Imhoff, Hartmut Kliemt (eds): Standardisierung in der Medizin, Stuttgart: Schattauer, pp. 33-37.
Gandjour, A., Günster, C., Lauterbach, K., Klauber, J., 2002, Mindestmengen in der stationären Versorgung: bundesweite Analyse ausgewählter Interventionen und Forschungsbedarf, in: Michael Arnold, Jürgen Klauber, Henner Schellschmidt (eds): Krankenhaus-Report 2002, Stuttgart: Schattauer, pp. 189-201.
Lauterbach, K., Gandjour, A., 2001, Instrumente zur Ressourcenverteilung im Gesundheitswesen, in: Matthias Schrappe, Karl Wilhelm Lauterbach (eds): Gesundheitsökonomie, Qualitätsmanagement und Evidence-based Medicine, Stuttgart: Schattauer, pp. 124-132.
Gandjour, A., Lauterbach, K., 2000, Eine systematische Übersicht zu Kosten-Nutzen-Analysen ergometrischer Untersuchungen, in: Herbert Löllgen, Erland Erdmann (eds): Ergometrie, 2., vollst. überarb. Aufl., Heidelberg: Springer, pp. 377-388.
Gandjour, A., Günster, C., Lauterbach, K., Klauber, J., 2002, Mindestmengen in der stationären Versorgung: bundesweite Analyse ausgewählter Interventionen und Forschungsbedarf, in: Michael Arnold, Jürgen Klauber, Henner Schellschmidt (eds): Krankenhaus-Report 2002, Stuttgart: Schattauer, pp. 189-201.
Lauterbach, K., Gandjour, A., 2001, Instrumente zur Ressourcenverteilung im Gesundheitswesen, in: Matthias Schrappe, Karl Wilhelm Lauterbach (eds): Gesundheitsökonomie, Qualitätsmanagement und Evidence-based Medicine, Stuttgart: Schattauer, pp. 124-132.
Gandjour, A., Lauterbach, K., 2000, Eine systematische Übersicht zu Kosten-Nutzen-Analysen ergometrischer Untersuchungen, in: Herbert Löllgen, Erland Erdmann (eds): Ergometrie, 2., vollst. überarb. Aufl., Heidelberg: Springer, pp. 377-388.
Schnell, G., Gandjour, A., Lauterbach, K., 2005. Effects of increased drug copayments on the demand for drugs and physician visits in Germany, Sozialwissenschaftlicher Fachinformationsdienst (1) pp. 11-23.
Gandjour, A., Lauterbach, K., 2002. Medizinische Ethik und Ökonomie im Gesundheitswesen: ein unvereinbarer Gegensatz?, Versicherungsmedizin Jg. 54(2), pp. 57-58.
Schichtherle, S., Gandjour, A., Lauterbach, K., 2001. Beitrag der Gesundheitsökonomie und der Evidence Based Medicine (EBM) für Public Health, Zeitschrift für Gesundheitswissenschaften Jg. 8(4), pp. 25-30.
Gandjour, A., Lauterbach, K., 2001. Beurteilung der Strukturqualität von Leistungserbringern: Entwicklung eines Evidenz-basierten Fragebogens, Zeitschrift für ärztliche Fortbildung und Qualität im Gesundheitswesen Jg. 95(7), pp. 503-507.
Lorenz, W., Ollenschläger, G., Geraedts, M., Gerlach, F., Gandjour, A., Helou, A., Kirchner, H., Koller, M., Lauterbach, K., Reinauer, H., Sitter, H., Thomeczek, C., 2001. Das Leitlinien-Manual: Entwicklung und Implementierung von Leitlinien in der Medizin, Zeitschrift für ärztliche Fortbildung und Qualität Jg. 95(Suppl. I), pp. 1-84.
Hammes, H., Bertram, B., Bornfeld, N., Gandjour, A., Parandeh-Shab, F., Danne, D., Kroll, P., Lemmen, K., Look, D., 2000. Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie, Zeitschrift für praktische Augenheilkunde Jg. 21(10), pp. 491-499.
Gandjour, A., Lauterbach, K., 1999. Allokationsproblematik im Kontext beschränkter finanzieller Ressourcen, Der Internist Vol. 40(3), pp. 255-259.
Gandjour, A., Lauterbach, K., 1999. Systematische Qualitätssicherung durch Evidenz-basierte Medizin, Arbeit und Sozialpolitik Bd. 53(11/12), pp. 12-20.
Gandjour, A., Lauterbach, K., 2002. Medizinische Ethik und Ökonomie im Gesundheitswesen: ein unvereinbarer Gegensatz?, Versicherungsmedizin Jg. 54(2), pp. 57-58.
Schichtherle, S., Gandjour, A., Lauterbach, K., 2001. Beitrag der Gesundheitsökonomie und der Evidence Based Medicine (EBM) für Public Health, Zeitschrift für Gesundheitswissenschaften Jg. 8(4), pp. 25-30.
Gandjour, A., Lauterbach, K., 2001. Beurteilung der Strukturqualität von Leistungserbringern: Entwicklung eines Evidenz-basierten Fragebogens, Zeitschrift für ärztliche Fortbildung und Qualität im Gesundheitswesen Jg. 95(7), pp. 503-507.
Lorenz, W., Ollenschläger, G., Geraedts, M., Gerlach, F., Gandjour, A., Helou, A., Kirchner, H., Koller, M., Lauterbach, K., Reinauer, H., Sitter, H., Thomeczek, C., 2001. Das Leitlinien-Manual: Entwicklung und Implementierung von Leitlinien in der Medizin, Zeitschrift für ärztliche Fortbildung und Qualität Jg. 95(Suppl. I), pp. 1-84.
Hammes, H., Bertram, B., Bornfeld, N., Gandjour, A., Parandeh-Shab, F., Danne, D., Kroll, P., Lemmen, K., Look, D., 2000. Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie, Zeitschrift für praktische Augenheilkunde Jg. 21(10), pp. 491-499.
Gandjour, A., Lauterbach, K., 1999. Allokationsproblematik im Kontext beschränkter finanzieller Ressourcen, Der Internist Vol. 40(3), pp. 255-259.
Gandjour, A., Lauterbach, K., 1999. Systematische Qualitätssicherung durch Evidenz-basierte Medizin, Arbeit und Sozialpolitik Bd. 53(11/12), pp. 12-20.
Gandjour, A.
Vaccine uptake and incentives
Gandjour, A., Kourouklis, D.
Pharmaceutical Spending and Early-Stage Innovation in Pharmaceuticals in Europe: an Instrumental Variable Analysis
Gandjour, A., Shaikh, M.
Pharmaceutical Expenditure and Economic Growth
Gandjour, A., Shaikh, M.
Pharmaceutical Expenditure and Economic Growth: an Instrumental Variables Analysis
Gandjour, A., Shaikh, M.
Pharmaceutical Expenditure and Life Expectancy
Vaccine uptake and incentives
| 2023 World Congress on Health Economics, 2023, Cape Town. |
Gandjour, A., Kourouklis, D.
Pharmaceutical Spending and Early-Stage Innovation in Pharmaceuticals in Europe: an Instrumental Variable Analysis
| Health Economists' Study Group, HESG Winter 2017 Conference, 2017, Birmingham. |
Gandjour, A., Shaikh, M.
Pharmaceutical Expenditure and Economic Growth
| European Health Economics Association, 2nd EuHEA PhD student-supervisor conference, 2015, Paris. |
Gandjour, A., Shaikh, M.
Pharmaceutical Expenditure and Economic Growth: an Instrumental Variables Analysis
| Health Economics at Lancaster Research Group, 87th Health Economists' Study Group Meeting, 2015, Lancaster. |
Gandjour, A., Shaikh, M.
Pharmaceutical Expenditure and Life Expectancy
| International Health Economics Association, 11th World Congress, 2015, Mailand. |
OFFICE HOURS
During the lecture period
Thursday 4:00pm until 6:00pm on appointment
Room
3.50
OFFICE HOURS
During the lecture period
Thursday 4:00pm until 6:00pm on appointment
Room
3.50